Gyre Therapeutics GYRE
NASDAQ GYRE
$7.11 +0.11 (+1.57%)
At close: Oct 2, 2026 · 4:00 PM EDT

Gyre Therapeutics (GYRE) Liabilities and Shareholders Equity (2010 - 2026)

Updated

Gyre Therapeutics (GYRE) recorded Liabilities and Shareholders Equity of $199.26 million in Q2 2026, up 30.5% from $152.65 million a year earlier and up 23.0% from the prior quarter.

Analysis

Gyre Therapeutics (GYRE) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends

At the end of FY2025, Gyre Therapeutics reported Liabilities and Shareholders Equity of $219.76 million, up 75.2% from FY2024.

  • Annual Liabilities and Shareholders Equity has increased for four straight years, with a five-year compound annual growth rate of 18.3% (FY2020 to FY2025).
  • Across earlier years, Liabilities and Shareholders Equity came in at $125.41 million in FY2024 (+7.6%), $116.54 million in FY2023 (+37.5%), $84.75 million in FY2022 (+52.3%) and $55.66 million in FY2021 (-41.3%).
  • Quarterly Liabilities and Shareholders Equity has ranged from $9.96 million in Q3 2023 to $219.76 million in Q4 2025 over the past five years.
  • On a year-over-year basis, Liabilities and Shareholders Equity has increased for seven consecutive quarters, with growth averaging 28.3% over the last seven quarters.
  • Peak year-over-year performance for Liabilities and Shareholders Equity in the last five years was growth of 875.7% in Q2 2024, against a decline of 85.1% in Q2 2023 at the low end.
  • Per Business Quant, the preceding three quarters came in at $162.02 million (Q1 2026), $219.76 million (Q4 2025) and $159.38 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn 142.28 Bn
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn 201.06 Bn
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn 135.12 Bn
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn 129.80 Bn
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn 122.03 Bn
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn 115.83 Bn
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn 95.64 Bn
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn 49.36 Bn
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn 201.13 Bn
10 Gyre Therapeutics 742.24 Mn 544.95 Mn 26.90 Mn 199.26 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 199.26 Mn
Mar 31, 2026 162.02 Mn
Dec 31, 2025 219.76 Mn
Sep 30, 2025 159.38 Mn
Jun 30, 2025 152.65 Mn
Mar 31, 2025 129.79 Mn
Dec 31, 2024 125.41 Mn
Sep 30, 2024 125.24 Mn
Jun 30, 2024 120.93 Mn
Mar 31, 2024 122.01 Mn
Dec 31, 2023 116.54 Mn
Sep 30, 2023 9.96 Mn
Jun 30, 2023 12.39 Mn
Mar 31, 2023 18.75 Mn
Dec 31, 2022 84.75 Mn
Sep 30, 2022 31.02 Mn
Jun 30, 2022 83.37 Mn
Mar 31, 2022 40.27 Mn
Dec 31, 2021 55.66 Mn
Sep 30, 2021 78.54 Mn
API Access

Gyre Therapeutics Liabilities and Shareholders Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=GYRE&period=max&api_key=YOUR_API_KEY